Recommended prophylactic doses of enoxaparin (Lovenox) are associated with subprophylactic anti-Factor Xa (anti-Xa) levels. This study examines the safety and efficacy of anti-Xa-guided dosing of enoxaparin in pancreatic surgery.
Methods
Prospectively enrolled patients undergoing pancreatic surgery received enoxaparin dosing adjusted based on peak anti-Xa levels and were compared to a historical cohort of patients.
Results
Baseline characteristics were similar between the intervention and control groups. In the intervention group, 73.9% initially had subprophylactic peak anti-Xa levels. There were no differences in the venous thromboembolism (VTE) rates between the intervention and control groups (0% vs. 7.69%; P = .084), major bleeding events (4.35% vs. 2.56%; P = .627), RBC transfusion (15.2% vs. 25.6%; P = .257), or Hgb on discharge (9.82 vs. 9.44 g/dL; P = .244). Subtherapeutic anti-Xa levels were correlated with a higher BMI (P = .033), longer OR time (P = .011), and length of stay (P = .018).
Conclusions
Enoxaparin 40 mg once daily is associated with subprophylactic peak anti-Xa levels. Dose adjustment based on anti-Xa levels trended toward a lower rate of in-hospital VTE without an increase in bleeding or transfusion requirement.
FalangaARussoLMilesiVVignoliA. Mechanisms and risk factors of thrombosis in cancer. Crit Rev Oncol Hematol. 2017;118:79-83. doi:10.1016/j.critrevonc.2017.08.003
2.
OsborneNHWakefieldTWHenkePK. Venous thromboembolism in cancer patients undergoing major surgery. Ann Surg Oncol. 2008;15(12):3567-3578. doi:10.1245/s10434-008-0151-4
3.
DallosMCEisenbergerABBatesSE. Prevention of venous thromboembolism in pancreatic cancer: breaking down a complex clinical dilemma. Oncologist. 2020;25:132-139. doi:10.1634/theoncologist.2019-0264.
4.
BergqvistDAgnelliGCohenAT, et al.Duration of prophylaxis against venous thromboembolism with enoxaparin after surgery for cancer. N Engl J Med. 2002;346(13):975-980. doi:10.1056/NEJMoa012385
5.
De MartinoRRGoodneyPPSpanglerEL, et al.Variation in thromboembolic complications among patients undergoing commonly performed cancer operations. J Vasc Surg. 2012;55(4):1035-1014e4. doi:10.1016/j.jvs.2011.10.129
6.
RuffSMWeberKTKhaderA, et al.Venous thromboembolism in patients with cancer undergoing surgical exploration. J Thromb Thrombolysis. 2019;47(2):316-323. doi:10.1007/s11239-018-1774-3
7.
AgnelliGBolisGCapussottiL, et al.A clinical outcome-based prospective study on venous thromboembolism after cancer surgery: the @RISTOS project. Ann Surg. 2006;243(1):89-95. doi:10.1097/01.sla.0000193959.44677.48
8.
TrinhVQKarakiewiczPISammonJ, et al.Venous thromboembolism after major cancer surgery: temporal trends and patterns of care. JAMA Surg. 2014;149(1):43-49. doi:10.1001/jamasurg.2013.3172
9.
GrosseSDNelsonRENyarkoKARichardsonLCRaskobGE. The economic burden of incident venous thromboembolism in the United States: a review of estimated attributable healthcare costs. Thromb Res. 2016;137:3-10. doi:10.1016/j.thromres.2015.11.033
10.
DallosMCEisenbergerABBatesSE. Prevention of venous thromboembolism in pancreatic cancer: breaking down a complex clinical dilemma. Oncologist. 2020;25(2):132-139. doi:10.1634/theoncologist.2019-0264
11.
FrèreCBournetBBenzidiaI, et al.Venous thromboembolism and pancreatic cancer. J Med Vasc. 2018;43(4):246-254. doi:10.1016/j.jdmv.2018.05.003
12.
OhashiYIkedaMKunitohH, et al.Venous thromboembolism in pancreatic cancer patients: report of baseline data from the multicentre, prospective cancer-VTE registry. Jpn J Clin Oncol. 2020;50(11):1246-1253. doi:10.1093/jjco/hyaa112
13.
GouldMKGarciaDAWrenSM, et al.Prevention of VTE in nonorthopedic surgical patients. Antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2012;141(2 suppl L):e227S-e277S. doi:10.1378/chest.11-2297
14.
LymanGHCarrierMAyC, et al.American society of hematology 2021 guideliens for management of venous thromboembolism: prevention and treament in patients with cancer. Blood Adv. 2021;5(4):927-974. doi:10.1182/bloodadvances.2020003442
15.
IqbalZCohenM. Enoxaparin: A pharmacologic and clinical review. Expet Opin Pharmacother. 2011;12(7):1157-1170. doi:10.1517/14656566.2011.570261
16.
WeitzJI. Low-molecular-weight heparins. N Engl J Med. 1997;337(10):688-698. doi:10.1056/NEJM199709043371007
17.
NutescuEASpinlerSAWittkowskyADagerWE. Anticoagulation: low-molecular-weight heparins in renal impairment and obesity: Available evidence and clinical practice recommendations across medical and surgical settings. Ann Pharmacother. 2009;43(6):1064-1083. doi:10.1345/aph.1L194
18.
WeiMYWardSM. The anti-factor Xa range for low molecular weight heparin thromboprophylaxis. Hematol Rep. 2015;7(4):5844.
19.
ClarkNP. Low-molecular-weight heparin use in the obese, elderly, and in renal insufficiency. Thromb Res. 2008;123 Suppl 1(Suppl 1):S58-S61. doi:10.1016/j.thromres.2008.08.005
20.
MassarwehNNAnayaDAKougiasP, et al.Variation and impact of multiple complications on failure to rescue after inpatient surgery. Ann Surg. 2016;266:59-65. doi:10.1097/SLA.0000000000001917
21.
CostantiniTWMinEBoxK, et al.Dose adjusting enoxaparin is necessary to achieve adequate venous thromboembolism prophylaxis in trauma patients. J Trauma Acute Care Surg. 2013;74(1):128-133. doi:10.1097/TA.0b013e3182788fa7
22.
SteinPDMattaFDalenJE. Is the campaign to prevent VTE in hospitalized patients working?Chest. 2011;139(6):1317-1321. doi:10.1378/chest.10-1622
23.
DeitelzweigSBJohnsonBHLinJSchulmanKL. Prevalence of clinical venous thromboembolism in the USA: current trends and future projections. Am J Hematol. 2011;86(2):217-220. doi:10.1002/ajh.21917
24.
LinHFaraklasICochranASaffleJ. Enoxaparin and antifactor Xa levels in acute burn patients. J Burn Care Res. 2011;32:1-5.
25.
PannucciCJFlemingKIMomeniAPrazakAMAgarwalJRockwellWB. Twice-daily enoxaparin among plastic surgery inpatients. Plast Reconstr Surg. 2018;141:1580-1590.
26.
LiuJHEtzioniDAO’ConnellJBMaggardMAKoCY. Using volume criteria: do California hospitals measure up?J Surg Res. 2003;113:96-101.
27.
PannucciCJFlemingKIBertolacciniCBPrazakAMHuangLCPickronTB. Assessment of anti-factor Xa levels of patients undergoing colorectal surgery given once-daily enoxaparin prophylaxis. JAMA Surg. 2019;154(8):697-704. doi:10.1001/jamasurg.2019.1165
28.
BaumgartnerJMMcKenzieSBlockSCostantiniTWLowyAM. Prophylactic enoxaparin doses may be inadequate in patients undergoing abdominal cancer surgery. J Surg Res. 2018;221:183-189. doi:10.1016/j.jss.2017.08.053
29.
KrammeKSarrafPMuneneG. Prophylactic enoxaparin adjusted by anti-Factor Xa peak levels compared with recommended thromboprophylaxis and rates of clinically evident venous thromboembolism in surgical oncology patients. J Am Coll Surg. 2020;230(3):314-321.
30.
BetheaASamantaDDeshaiesDRichmondBK. Determination of optimal weight-based enoxaparin dosing and associated clinical factors for achieving therapeutic anti-Xa assays for deep venous thrombosis prophylaxis. J Am Coll Surg. 2019;229:295-304.
31.
LaposataMGreenDVan CottEMBarrowcliffeTWGoodnightSHSosolikRC. College of American Pathologists conference XXXI on laboratory monitoring of anticoagulant therapy: the clinical use and laboratory monitoring of low-molecular-weight hepearin, danaparoid, hirudin and related compounds, and argatroban. Arch Pathol Lab Med. 1998;122(9):799-807.
